Collecting Samples for Hematologic Cancer Research

This study is collecting and storing samples of tissue, blood, and body fluids from patients with hematologic cancers (cancers affecting blood, bone marrow, and lymph nodes) like leukemia, lymphoma, and multiple myeloma. The goal is to create a central facility to process and store these samples for future research. Researchers hope these samples will help them better understand, diagnose, and predict the course of these cancers over the next 30 years. You may be able to join if you are 18 to 120 years old and have been diagnosed with an abnormal hematopoietic/lymphoid cancer. The study status is currently unclear.

Study design
This is an observational study, meaning researchers are collecting information without providing specific treatments. It plans to enroll up to 15,000 participants.
What's involved
You would provide tissue, blood, and body fluid samples during your routine diagnostic or treatment procedures.
Compensation
Not stated in the trial record.
Follow-up
Samples will be collected for ongoing studies over a period of 30 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01137643

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Recruiting
Not specifiedAges 18+Observational
UNC Lineberger Comprehensive Cancer Center
~15,000 participants
Updated 2025-10-27 on ClinicalTrials.gov
What's tested:biologic sample preservation procedurecytology specimen collection procedure

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Tissue, blood, and body fluid samples collection for ongoing diagnostic, prognostic, or immune-monitoring studies
Measured over 30 years
+1 more outcome measured
Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Nonmalignant Neoplasm
1 sites across 1 states
North Carolina1
  • Paul Armistead, MD · PRINCIPAL_INVESTIGATOR · UNC Lineberger Comprehensive Cancer Center

Opens a ready-to-send draft in your own email app — review before sending.

  • Tissue, blood, and body fluid samples collection for ongoing diagnostic, prognostic, or immune-monitoring studies30 years
  • Development of a centralized, quality-controlled, quality-assured facility for the procurement, processing, storage, and distribution of normal and malignant tissue specimens and corresponding blood specimens30 years